Anthrax Drugs Pipeline Market Research Report 2022: Comprehensive Insights on 10+ Companies and 10+ Pipeline Drugs – ResearchAndMarkets.com
March 4, 2022DUBLIN–(BUSINESS WIRE)–The “Anthrax – Pipeline Insight, 2022” clinical trials has been added to ResearchAndMarkets.com’s offering.
The publisher’s, “Anthrax – Pipeline Insight, 2022,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Anthrax pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
‘Anthrax – Pipeline Insight, 2022’ report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Anthrax pipeline landscape is provided which includes the disease overview and Anthrax treatment guidelines.
The assessment part of the report embraces, in depth Anthrax commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Anthrax collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Anthrax R&D. The therapies under development are focused on novel approaches to treat/improve Anthrax.
Anthrax Emerging Drugs Chapters
This segment of the Anthrax report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Anthrax Emerging Drugs
GC1109: GC Pharma
GC1109 targets as its antigen the anthrax toxin which, in infection, serves as a receptor binder. This vaccine is obtained by cultivating and purifying genetically engineered Bacillus brevis. In the phases 1 and 2 of clinical trials, GC1109 has displayed an excellent safety profile and dose-dependent immunogenicity. Currently, it is in phase II stage of development.
AV7909: Emergent BioSolutions
The vaccine candidate AV7909 is being developed for post-exposure prophylaxis of disease resulting from suspected or confirmed Bacillus anthracis exposure, in conjunction with the recommended course of antimicrobial therapy. AV7909 is comprised of Anthrax Vaccine Adsorbed (AVA) in combination with an adjuvant. The vaccine is currently in phase III stage of development.
Further product details are provided in the report….
Anthrax: Therapeutic Assessment
This segment of the report provides insights about the different Anthrax drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Anthrax
There are approx. 10+ key companies which are developing the therapies for Anthrax. The companies which have their Anthrax drug candidates in the most advanced stage, i.e. phase III include, Emergent BioSolutions.
Key Players
- GC Pharma
- Emergent BioSolutions
- BlueWillow Biologics
- Paratek Pharmaceuticals
- Altimmune
- Greffex
- Planet Biotechnology
- Integrated BioTherapeutics
- DEINOVE
- Hawaii Biotech
- VLP Biotech
- Aphios Corporation
- Enesi
Key Products
- GC1109
- AV7909
- BW 1010
- Omadacycline
- rPA 102
- NasoShield
- Research programme: DNA vaccines
- PBI 220
- Ba ISTAb
- DNV3837
Key Topics Covered:
Introduction
Executive Summary
Anthrax: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Anthrax – The Publisher’s Analytical Perspective
Late Stage Products (Phase III)
- Comparative Analysis
AV7909: Emergent BioSolutions
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report
Mid Stage Products (Phase II)
- Comparative Analysis
GC1109: GC Pharma
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report
Early Stage Products (Phase I)
- Comparative Analysis
Intransal anthrax vaccine: Altimmune
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report
Preclinical and Discovery Stage Products
- Comparative Analysis
PBI 220: Planet Biotechnology
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report
Inactive Products
- Comparative Analysis
- Anthrax Key Companies
- Anthrax Key Products
- Anthrax- Unmet Needs
- Anthrax- Market Drivers and Barriers
- Anthrax- Future Perspectives and Conclusion
- Anthrax Analyst Views
- Anthrax Key Companies
Appendix
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/xl901s
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900